Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum Magnesium Changes with Dapagliflozin in Asymptomatic Heart Failure (DAPA-EAT sample retrospective study)
jRCT1050240257Recruiting
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in heart failure (HF), sponsored by none. Primary endpoint: Change in serum magnesium levels from baseline to 24 weeks. Started Jan 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT1050240257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050240257.